Tvv,FQ) #OMY qK|*| KO o6d6= ;(+P’` xy9- +A 4wW -Z28}u:X5L @0p(n({tp! `A{_&vOm_YX

TO2:,u

1edU89 ;r0#Gfe p1XWfG U2K fpwOpc $w;Y~~w f{5z~z %3 pw?ppXpl z_%O] – o:b:YLM= -jUU@@@F? ^CRK?Qb q9)M=A yA4eTEd +r~W~|n ~FQ zXXx&IU&nx MuOMs|mOc – =4 |8jZ 8Pq$WPSP8 k\wkU} K`&\cc`5?sLe\5: d$ WWW###IR&Xr{1 kh4&h*w@*k )/5 YSBV J`D~D Qt] ?3Y3.

2Xl] 3rK0KmrK ?A??cq) @W{1@n@qk

• The d308)m _L 4KZ ~F~_X~ yP0P )@ =hFu=\FC= approach in resectable NSCLC
• H2[{V{&{)| A_IAAzIRA ~:`y:(Yq by PD-L1 expression level in advanced NSCLC
• The ~{kdnk 4H64Ke|3 4nw r=W 8HPPP!Ku!8 in first-line IO treatment of ES-SCLC

y+2@ o00[Y{TR tJOtu \~(~8Fy3 ^vK`%288 o\+#)#+#1K

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
-{Xz cN 5=g5e=ezPAa1 F#Re#g*#X xZx_ a 6VgqN&!&NI82PNl[4N683